CO6260083A2 - Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentos - Google Patents
Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentosInfo
- Publication number
- CO6260083A2 CO6260083A2 CO10095026A CO10095026A CO6260083A2 CO 6260083 A2 CO6260083 A2 CO 6260083A2 CO 10095026 A CO10095026 A CO 10095026A CO 10095026 A CO10095026 A CO 10095026A CO 6260083 A2 CO6260083 A2 CO 6260083A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- alkylene
- independently
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un compuesto de la fórmula Iy/o cualquier forma estereoisomérica o tautomérica del compuesto de la fórmula I y/o mezclas de estas formas en cualquier proporción, y/o una sal fisiológicamente compatible del compuesto de la fórmula I, en la que Q1 es un átomo de hidrógeno, -alquilo (C1-C6), - cicloalquilo (C3-C6), -OH, -O-alquilo (C1-C6) o -O-cicloalquilo (C3-C6), donde cada uno de alquilo y cicloalquilo está sin sustituir o mono-, di- o trisustituido independientemente con -alquilo (C1-C4), -cicloalquilo (C3-C6), OH, -O-alquilo (C1-C6) o -O-cicloalquilo (C3-C6), donde algunos o todos los átomos de hidrógeno en el alquilo o cicloalquilo pueden reemplazarse por flúor, Q2 y Q3 son iguales o diferentes y cada uno es independientemente un átomo de hidrógeno, -alquilo (C1-C6) o -cicloalquilo (C3-C6), donde algunos o todos los átomos de hidrógeno en el alquilo o cicloalquilo pueden reemplazarse por flúor, R1, R2 y R3 son iguales o diferentes y cada uno es independientemente un átomo de hidrógeno, -alquilo (C1-C6), -cicloalquilo (C3-C6), -O-alquilo (C1-C8), -O-cicloalquilo (C3-C6), -alquileno (C0-C4)-C(O)-N(R11)-R12, -alquileno (C0-C4)-C(O)-O-R11, -alquileno (C0-C4)-C(O)- R11, -alquileno (C0-C4)-N(R11)-R12, -alquileno (C0-C4)-N(R11)-C(O)-R12, halógeno, OH, -CN, -NO2, -SO2CH3, -SO2CF3, -SF5, - Si[alquilo (C1-C4)]3, -alquileno (C1-C6)-O-alquilo (C1-C6), -O-alquileno (C1-C6)-O-alquilo (C1-C6), -O-alquileno (C0-C4)-arilo (C6-C14) donde el arilo está sin sustituir o mono-, di- o trisustituido independientemente con -O-alquilo (C1-C6), -alquilo (C1-C4), OH, -cicloalquilo (C3-C6) o O-cicloalquilo (C3-C6), -O-alquileno (C1-C4)-cicloalquilo (C3-C6) -Het (C4-C15) donde Het está sin sustituir o mono-, di- o trisustituido independientemente con -alquilo (C1-C4), -cicloalquilo (C3-C6), OH, -O-alquilo (C1-C6) o -O-cicloalquilo (C3-C6), o -O-alquileno (C1-C6)-O-alquileno (C1-C6)- O-alquilo (C1-C6), donde cada uno del alquilo, alquileno y cicloalquilo está sin sustituir o mono-, di-o trisustituido independientemente con-alquilo (C1-C4), - cicloalquilo (C3-C6), OH, -O-alquilo (C1-C6), -arilo (C6-C14), donde el arilo está sin sustituir o mono-, di-, tri-, tetra- o pentasustituido independientemente con halógeno, -alquilo (C1-C4), -cicloalquilo (C3-C6), ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290112 | 2008-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260083A2 true CO6260083A2 (es) | 2011-03-22 |
Family
ID=39539711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10095026A CO6260083A2 (es) | 2008-02-05 | 2010-08-04 | Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentos |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8076336B2 (es) |
| EP (1) | EP2240487B1 (es) |
| JP (1) | JP5526040B2 (es) |
| KR (1) | KR20100114514A (es) |
| CN (1) | CN101981034B (es) |
| AR (1) | AR070410A1 (es) |
| AT (1) | ATE537172T1 (es) |
| AU (1) | AU2009211887B2 (es) |
| BR (1) | BRPI0907486A2 (es) |
| CA (1) | CA2713550C (es) |
| CL (1) | CL2009000236A1 (es) |
| CO (1) | CO6260083A2 (es) |
| CY (1) | CY1113228T1 (es) |
| DK (1) | DK2240487T3 (es) |
| ES (1) | ES2379447T3 (es) |
| HK (1) | HK1149011A1 (es) |
| HR (1) | HRP20120230T1 (es) |
| IL (1) | IL207205A0 (es) |
| MA (1) | MA32061B1 (es) |
| MX (1) | MX2010008490A (es) |
| MY (1) | MY152040A (es) |
| NZ (1) | NZ587141A (es) |
| PA (1) | PA8814801A1 (es) |
| PE (1) | PE20091455A1 (es) |
| PL (1) | PL2240487T3 (es) |
| PT (1) | PT2240487E (es) |
| RS (1) | RS52264B (es) |
| RU (1) | RU2499797C2 (es) |
| SI (1) | SI2240487T1 (es) |
| TW (1) | TW200946532A (es) |
| WO (1) | WO2009097970A1 (es) |
| ZA (1) | ZA201004467B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2663528A1 (en) * | 2006-09-18 | 2008-03-27 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of c-met and uses thereof |
| CA2713551C (en) | 2008-02-05 | 2016-06-14 | Sanofi-Aventis | Triazolium salts as par1 inhibitors, production thereof, and use as medicaments |
| US8673890B2 (en) | 2009-10-29 | 2014-03-18 | Janssen Pharmaceutica Nv | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist |
| BR112021025588A2 (pt) * | 2019-06-19 | 2022-02-01 | Nmd Pharma As | Processo para a preparação dos inibidores de canal de cloreto clc-1 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4578464A (en) | 1983-11-22 | 1986-03-25 | Merrell Dow Pharmaceuticals Inc. | 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds |
| HUT77130A (hu) * | 1994-09-16 | 1998-03-02 | Takeda Chemical Industries Ltd. | [1,2,4] Triazolo[1,5-b]piridazin-származékok, eljárás előállításukra, és a vegyületeket tartalmazó gyógyszerkészítmények |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| US7488742B2 (en) | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| IL158491A0 (en) * | 2001-04-19 | 2004-05-12 | Eisai Co Ltd | 2-iminopyrrolidine derivatives |
| CA2448509A1 (en) | 2001-05-25 | 2002-12-05 | Mochida Pharmaceutical Co., Ltd. | 4-hydroxypiperidine derivatives having analgesic activity |
| WO2003031442A1 (fr) | 2001-10-05 | 2003-04-17 | Takeda Chemical Industries, Ltd. | Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation |
| HUP0500443A3 (en) | 2001-10-18 | 2009-12-28 | Schering Corp | Himbacine analogues as thrombin receptor antagonists and pharmaceutical compositions containing them |
| SI2065384T1 (sl) | 2002-04-16 | 2011-05-31 | Schering Corp | Tricikliäśni trombin receptor antagonist |
| KR20050104376A (ko) | 2003-02-19 | 2005-11-02 | 에자이 가부시키가이샤 | 고리형상 벤즈아미딘 유도체의 제조방법 |
| TW200531688A (en) | 2004-03-05 | 2005-10-01 | Hoffmann La Roche | Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents |
| WO2006051648A1 (ja) | 2004-11-09 | 2006-05-18 | Eisai R & D Management Co., Ltd. | トロンビン受容体アンタゴニストを有効成分とするくも膜下出血に伴う血管攣縮の治療剤 |
| BRPI0620292B1 (pt) * | 2005-12-21 | 2021-08-24 | Janssen Pharmaceutica N. V. | Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto |
| DE102006025318A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung |
| DE102006036023A1 (de) * | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
| SI2242740T1 (sl) | 2008-02-05 | 2013-03-29 | Sanofi | SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila |
| WO2009097973A2 (de) | 2008-02-05 | 2009-08-13 | Sanofi-Aventis | Imidazopyridazine als parl-inhibitoren, ihre herstellung und verwendung als arzneimittel |
| CA2713551C (en) | 2008-02-05 | 2016-06-14 | Sanofi-Aventis | Triazolium salts as par1 inhibitors, production thereof, and use as medicaments |
| US8394823B2 (en) | 2008-04-11 | 2013-03-12 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as DGAT1 inhibitors |
| WO2009126624A1 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
-
2009
- 2009-01-23 CN CN2009801115086A patent/CN101981034B/zh not_active Expired - Fee Related
- 2009-01-23 ES ES09708289T patent/ES2379447T3/es active Active
- 2009-01-23 PT PT09708289T patent/PT2240487E/pt unknown
- 2009-01-23 AT AT09708289T patent/ATE537172T1/de active
- 2009-01-23 RU RU2010136957/04A patent/RU2499797C2/ru not_active IP Right Cessation
- 2009-01-23 MY MYPI20103226 patent/MY152040A/en unknown
- 2009-01-23 WO PCT/EP2009/000406 patent/WO2009097970A1/de active Application Filing
- 2009-01-23 MX MX2010008490A patent/MX2010008490A/es active IP Right Grant
- 2009-01-23 AU AU2009211887A patent/AU2009211887B2/en not_active Ceased
- 2009-01-23 NZ NZ587141A patent/NZ587141A/en not_active IP Right Cessation
- 2009-01-23 EP EP09708289A patent/EP2240487B1/de active Active
- 2009-01-23 SI SI200930192T patent/SI2240487T1/sl unknown
- 2009-01-23 RS RS20120103A patent/RS52264B/en unknown
- 2009-01-23 DK DK09708289.5T patent/DK2240487T3/da active
- 2009-01-23 CA CA2713550A patent/CA2713550C/en not_active Expired - Fee Related
- 2009-01-23 PL PL09708289T patent/PL2240487T3/pl unknown
- 2009-01-23 JP JP2010545378A patent/JP5526040B2/ja not_active Expired - Fee Related
- 2009-01-23 BR BRPI0907486-4A patent/BRPI0907486A2/pt not_active IP Right Cessation
- 2009-01-23 KR KR1020107017452A patent/KR20100114514A/ko not_active Application Discontinuation
- 2009-02-03 TW TW098103334A patent/TW200946532A/zh unknown
- 2009-02-03 CL CL2009000236A patent/CL2009000236A1/es unknown
- 2009-02-03 AR ARP090100348A patent/AR070410A1/es not_active Application Discontinuation
- 2009-02-03 PE PE2009000154A patent/PE20091455A1/es not_active Application Discontinuation
- 2009-02-03 PA PA20098814801A patent/PA8814801A1/es unknown
-
2010
- 2010-06-24 ZA ZA2010/04467A patent/ZA201004467B/en unknown
- 2010-07-25 IL IL207205A patent/IL207205A0/en unknown
- 2010-08-04 CO CO10095026A patent/CO6260083A2/es active IP Right Grant
- 2010-08-04 MA MA33059A patent/MA32061B1/fr unknown
- 2010-08-05 US US12/851,189 patent/US8076336B2/en not_active Expired - Fee Related
-
2011
- 2011-03-30 HK HK11103239.2A patent/HK1149011A1/xx not_active IP Right Cessation
- 2011-09-23 US US13/243,118 patent/US9079906B2/en not_active Expired - Fee Related
-
2012
- 2012-03-13 HR HR20120230T patent/HRP20120230T1/hr unknown
- 2012-03-14 CY CY20121100256T patent/CY1113228T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| DK3699181T3 (da) | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat | |
| HK1216527A1 (zh) | -二氫吡唑幷 吡嗪- -酮化合物及其作爲 受體的負性別構調節物的用途 | |
| PE20200387A1 (es) | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| HK1220121A1 (zh) | 取代的 -二氫咪唑並 喹唑啉治療淋巴瘤的用途 | |
| PE20150666A1 (es) | Inhibidores de serina/treonina cinasa | |
| CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| PE20141973A1 (es) | Compuestos de heterociclilo como inhibidores de mek | |
| CR9398S (es) | Contenedor | |
| SG11201600821SA (en) | Waste incinerator ash as aerating agent for the manufacture of lightweight construction materials | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| TR201900662T4 (tr) | Cb2 reseptör antagonistleri olarak triazolo[4,5-d]pirimidin türevleri. | |
| CO6592042A2 (es) | Derivados de n3-sustituido -n1-sulfonil-5-fluorpirimidinona | |
| GT200800075S (es) | Diseño de embudo | |
| GT200700098S (es) | Envase | |
| CR20150254A (es) | Compuestos quimicos | |
| AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
| WO2008111239A1 (ja) | 帯電防止剤およびその用途 | |
| CO6260083A2 (es) | Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentos | |
| PE20170683A1 (es) | Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2 | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| CO6311103A2 (es) | Sales de triazolio como inhibidores del par1 produccion de las mismas y uso como medicamentos | |
| PE20170009A1 (es) | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |